Equities

Centessa Pharmaceuticals PLC

Centessa Pharmaceuticals PLC

Actions
  • Price (EUR)16.20
  • Today's Change-0.50 / -2.99%
  • Shares traded0.00
  • 1 Year change+167.77%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 15:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments257394595
Total Receivables, Net392717
Total Inventory------
Prepaid expenses181416
Other current assets, total1.623.270.99
Total current assets315438629
Property, plant & equipment, net131.170.16
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets2.555.390.70
Total assets360444630
LIABILITIES
Accounts payable12148.07
Accrued expenses272316
Notes payable/short-term debt000
Current portion long-term debt/capital leases----0
Other current liabilities, total0.111.580.77
Total current liabilities393825
Total long term debt767076
Total debt767076
Deferred income tax------
Minority interest------
Other liabilities, total8.92038
Total liabilities124108138
SHAREHOLDERS EQUITY
Common stock0.270.270.25
Additional paid-in capital987939876
Retained earnings (accumulated deficit)(753)(602)(386)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.49(1.5)0.69
Total equity236336492
Total liabilities & shareholders' equity360444630
Total common shares outstanding999590
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.